focus -WSS

focus

author：leisure time 2025-09-02 08:23:19 - browse：49

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： The biotech scorecard for Q3: 15 stock

hotspot

WSS

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Covid vaccine financial winners and losers, from Pfizer to Novavax

Readout Newsletter: Merck, Vertex, and Viking updates

Oprah kicked off a national conversation on obesity. Let's have it

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Use doctors trained outside the U.S. to ease the physician shortage

knowledge

focus

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Washington mulls new rules to avert another Change Healthcare

What does generative AI mean for health care? We asked experts

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Guidelines to prevent youth baseball injuries need more muscle

UpToDate has a racism problem: Dr. Stanley Goldfarb

As demand for Covid shots wanes, Moderna seeks its next success

Washington mulls new rules to avert another Change Healthcare

Alkermes shareholders re

AstraZeneca lung cancer study comes in below expectations

focus

The biotech scorecard for Q3: 15 stock

A letter from the executive editor: The 2023 STATUS List

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

States should stop sabotaging methadone treatment reform

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Decaf coffee targeted by food safety group under obscure FDA rule

hotspot

knowledge

explore

hotspot